Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
NCT04563195 · Matthew C. Baker · PHASE2/PHASE3 · withdrawn · last registry update 2022-01-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug unavailable” | – | Registry record, Matthew C. Baker |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-18Also stopped (withdrawn): xuna, Belimumab (Benlysta) (NCT05604742)
- 2023-01-09Results posted on the registry: University of Wisconsin, Madison, Belimumab (NCT03591380)
- 2023-01-09Also stopped (terminated): University of Wisconsin, Madison, Belimumab (NCT03591380)
- 2022-11-08Phase 3 first posted: Vera Therapeutics, Inc., Atacicept + Placebo (NCT05609812)
- 2022-05-24Results posted on the registry: Hospital for Special Surgery, New York, Belimumab + Mycophenolate Mofetil (NCT01670565)
- 2022-04-25Results posted on the registry: GlaxoSmithKline, Belimumab + Rituximab (NCT03312907)
- 2022-04-21Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Combination of Rituximab with subcutaneous belimumab + Combination of Rituximab with subcutaneous placebo (NCT05338190)
- 2022-03-02Phase 3 first posted: Peking University People's Hospital, Belimumab + Interleukin-2 (NCT05262686)
- 2021-10-15Results posted on the registry: Amgen, AMG 570 + AMG 570 Matching Placebo (NCT02618967)
- 2021-08-25Phase 3 first posted: University of Turin, Italy, Belimumab (NCT05020782)
- 2021-06-09Results posted on the registry: GlaxoSmithKline, Belimumab + Rituximab (NCT02631538)
- 2021-02-25Results posted on the registry: EMD Serono Research & Development Institute, Inc., Placebo + Atacicept 25 mg (NCT02808429)
- 2021-02-25Also stopped (terminated): EMD Serono Research & Development Institute, Inc., Placebo + Atacicept 25 mg (NCT02808429)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision